Literature DB >> 11468190

Characterization of the T-cell repertoire in autologous graft-versus-host disease (GVHD): evidence for the involvement of antigen-driven T-cell response in the development of autologous GVHD.

Y Miura1, C J Thoburn, E C Bright, M Sommer, S Lefell, M Ueda, S Nakao, A D Hess.   

Abstract

Administration of cyclosporine A (CsA) after autologous stem cell transplantation elicits an autoimmune syndrome with pathology similar to graft-versus-host disease (GVHD). This syndrome, termed autologous GVHD, is associated with the appearance of autoreactive T cells directed at major histocompatibility class (MHC) class II antigens. In the rat model of autologous GVHD, clonal analysis reveals that the effector T cells are highly conserved and recognize a peptide from the invariant chain peptide presented by MHC class II. Although human autologous GVHD effector T cells share a similar phenotypic specificity, clonality of the response in humans has not been determined. To examine the human effector T-cell response, the T-cell repertoire of peripheral blood lymphocytes was assessed by complementarity-determining region 3 (CDR3) size distribution analysis and T-cell clonotype analysis in 26 patients treated with CsA after transplantation. Autologous GVHD developed in 3 of 4 patients with human leukocyte antigen (HLA)-DRB1*0701, and clonal expansions of beta-chain variable region (BV)16(+) T cells were shared. Clonal expansions within BV15(+) and BV22(+) T cells were also detected in 4 of 6 patients with HLA-DRB1*1501 and in 3 of 4 patients with HLA-DRB1*0401, respectively. Sequencing of BV16 cDNA for which the CDR3 size pattern exhibited apparent clone predominance revealed an identical CDR3 peptide sequence in 2 different patients, one with HLA-DRB1*0701 and the other with HLA-DRB1*1502. These findings indicate that the discrete antigen-driven expansion of T cells is involved in autologous GVHD. (Blood. 2001;98:868-876)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468190     DOI: 10.1182/blood.v98.3.868

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

1.  Emergence of T cells that recognize nonpolymorphic antigens during graft-versus- host disease.

Authors:  Hemalatha Rangarajan; Maryam Yassai; Hariharan Subramanian; Richard Komorowski; Megan Whitaker; Jack Gorski; William R Drobyski
Journal:  Blood       Date:  2012-04-10       Impact factor: 22.113

2.  Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cells.

Authors:  Christopher G Kanakry; Allan D Hess; Christopher D Gocke; Christopher Thoburn; Ferdynand Kos; Christian Meyer; Janet Briel; Leo Luznik; B Douglas Smith; Hyam Levitsky; Judith E Karp
Journal:  Blood       Date:  2010-10-08       Impact factor: 22.113

3.  Immunophenotypic and molecular comparison between allogeneic and autologous graft-vs-host disease of the skin: A retrospective study using immunohistochemical and proteomics methods.

Authors:  Julia S Lehman; Shahrukh K Hashmi; Hillard M Lazarus; Rokea A El-Azhary; Lawrence E Gibson; William J Hogan; Mark R Litzow; Mrinal S Patnaik; Francis Buadi; Martha Q Lacy; Surendra Dasari; Patrick Vanderboom; Alexander Meves
Journal:  J Cutan Pathol       Date:  2017-09-14       Impact factor: 1.587

4.  Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphoma.

Authors:  Javier Bolaños-Meade; Elizabeth Garrett-Mayer; Leo Luznik; Viki Anders; Jennifer Webb; Ephraim J Fuchs; Carol Ann Huff; William Matsui; Ivan M Borrello; Robert Brodsky; Yvette L Kasamon; Lode J Swinnen; Ian W Flinn; Richard F Ambinder; Richard J Jones; Allan D Hess; Georgia B Vogelsang
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-03       Impact factor: 5.742

Review 5.  Role of immunotherapy in stem cell transplantation.

Authors:  Sally Arai; Hans G Klingemann
Journal:  Int J Hematol       Date:  2003-01       Impact factor: 2.490

Review 6.  Cord blood in regenerative medicine: do we need immune suppression?

Authors:  Neil H Riordan; Kyle Chan; Annette M Marleau; Thomas E Ichim
Journal:  J Transl Med       Date:  2007-01-30       Impact factor: 5.531

7.  Evaluation of the capacities of mouse TCR profiling from short read RNA-seq data.

Authors:  Yu Bai; David Wang; Wentian Li; Ying Huang; Xuan Ye; Janelle Waite; Thomas Barry; Kurt H Edelmann; Natasha Levenkova; Chunguang Guo; Dimitris Skokos; Yi Wei; Lynn E Macdonald; Wen Fury
Journal:  PLoS One       Date:  2018-11-15       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.